Biofil Chemicals & Pharmaceuticals Ltd Fiscal Year 2026 Results

Biofil Chemicals & Pharmaceuticals Ltd reported a net profit of ₹2.7860 crore for the year ended March 31, 2026. This marks a substantial increase from the ₹0.5578 crore profit recorded in the previous fiscal year.

Revenue from operations for FY26 stood at ₹28.3952 crore, a decrease from ₹33.4022 crore in FY25. The company attributed this decline to operational disruptions stemming from necessary factory renovations and upgrades to comply with revised Schedule M regulations for Drugs & Cosmetics.

Reader Takeaway: Profit boosted by asset sale, but revenue dips due to factory upgrades.

What just happened

Biofil Chemicals & Pharmaceuticals Ltd announced its financial results for the year ended March 31, 2026. The company reported a net profit of ₹2.7860 crore, a significant rise from ₹0.5578 crore in the prior year. However, revenue from operations decreased to ₹28.3952 crore from ₹33.4022 crore.

Why this matters

The increase in net profit was primarily driven by the disposal of an undertaking located in Indore to Formo Plast Private Limited. This non-recurring gain overshadowed a decline in revenue, which was impacted by factory renovations undertaken for regulatory compliance.

The backstory

The company's Pharma division saw its revenue fall from ₹26.6604 crore in FY25 to ₹18.9633 crore in FY26. Conversely, the Chemical division's revenue grew from ₹6.7418 crore to ₹9.4319 crore.

What changes now

Investors will be keen to see how the company's core operations perform once the factory renovations are complete and operations stabilize. The growth in the Chemical division may offer some buffer.

Risks to watch

Key risks include the sustainability of profits without asset disposal gains and the full impact of the operational disruptions on future revenue. The company's ability to recover revenue in its Pharma division is crucial.

Context metrics (time-bound)

For FY26, Biofil Chemicals reported total assets of ₹42.8481 crore and an operating cash flow of ₹-0.6049 crore. The audit opinion for the year was unmodified.

What to track next

Investors should monitor the company's performance in the upcoming quarters to assess the impact of the factory upgrades on its revenue and profitability, and the sustained growth of the chemical division.